Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Asterasys CoXKRX:450950 -4.29%23 EV-to-FCF is -331.61 as of Sep. 03, 2026. GuruFocus rates XKRX:450950 with a GF Score™ of 23/100. The stock has 4 warning signs investors should review. Among 408 Medical Devices & Instruments companies, Asterasys Co ranks worse than 245097.79% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Asterasys Co's Enterprise Value is ₩177,005 Mil.
Asterasys Co's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was ₩-534 Mil. Therefore, Asterasys Co's EV-to-FCF for today is -331.61.
The historical rank and industry rank for Asterasys Co's EV-to-FCF or its related term are showing as below:
XKRX:450950'
s EV-to-FCF Range Over the Past 10 Years
Min: -457.86 Med: 119.13 Max: 613.59
Current: -350.65
During the past 5 years, the highest EV-to-FCF of Asterasys Co was 613.59. The lowest was -457.86. And the median was 119.13.
XKRX:450950's EV-to-FCF is ranked worse than 100% of 408
companies
in the Medical Devices & Instruments industry
Industry Median: 24.28
vs XKRX:450950: -350.65
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Asterasys Co's PE Ratio (TTM) for today is calculated as:
Asterasys Co's share price for today is ₩5130.00.
Asterasys Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩162.000.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Asterasys Co EV-to-FCF Related Terms
Asterasys Co EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Asterasys Co's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XKRX:450950 vs ABT, SYK, MDT: EV-to-FCF Comparison
For the Medical Devices subindustry, Asterasys Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Asterasys Co EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Asterasys Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Asterasys Co's EV-to-FCF falls into.
Asterasys Co's current Enterprise Value is ₩177,005 Mil.
Asterasys Co's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-534 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Asterasys Co (XKRX:450950) has a EV-to-FCF of -331.61 as of Sep. 03, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Asterasys Co and its competitors. According to the industry distribution chart, Asterasys Co ranks #999999 out of 408 companies in the Medical Devices & Instruments industry.
Is Asterasys Co's EV-to-FCF too high?
Asterasys Co's current EV-to-FCF is -331.61. Based on the distribution chart, Asterasys Co ranks #999999 out of 408 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Asterasys Co has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Asterasys Co's EV-to-FCF compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Asterasys Co ranks #999999 out of 408 companies for EV-to-FCF. This places Asterasys Co in the lower half of its industry. The industry median EV-to-FCF is 24.28. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 24.28, based on 408 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Asterasys Co and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 24.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Asterasys Co's current EV-to-FCF is -331.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Asterasys Co stock overvalued right now?
Asterasys Co (XKRX:450950) has a current EV-to-FCF of -331.61. The current EV-to-FCF is -331.61. Asterasys Co's overall GF Score™ is 23/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Asterasys Co (XKRX:450950), the current EV-to-FCF is -331.61 as of Sep. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Asterasys Co Ltd is a professional healthcare and biomedical corporation based in Korea. It is engaged in the Manufacture of electro-diagnostic and electro-therapeutic apparatuses featuring body composition analyzers such as the InBalance series and HIFU systems such as the Liftera series, it provides total solutions with healthcare, skincare, and IoT-oriented services that can connect with its product portfolio.
23GF Score
Get the complete analysis for XKRX:450950
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKRX:450950 has been successfully added to your 
